 Shares of Icon NASDAQ:ICLR were unchanged after the company reported Q2 results.Quarterly Results Earnings per share fell 28.99 year over year to 1.20, which beat the estimate of 1.10.Revenue of 620,228,000 decreased by 10.78 from the same period last year, which beat the estimate of 598,770,000.Looking Ahead Q3 EPS expected between 6.00 and 6.50.View more earnings on ICLRQ3 revenue expected between 2,650,000,000 and 2,750,000,000.Price Action Companys 52-week high was at 194.17Companys 52-week low was at 104.28Price action over last quarter: Up 27.64Company Profile Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.See more from Benzinga Stocks That Hit 52-Week Highs On Wednesday Earnings Scheduled For July 22, 2020 Stocks That Hit 52-Week Highs On TuesdayC 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. 